Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma

PURPOSE: Despite the remarkable activity of BTK inhibitors (BTKi) in relapsed B-cell non–Hodgkin lymphoma (B-NHL), no clinically-relevant biomarker has been associated to these agents so far. The relevance of phosphoproteomic profiling for the early identification of BTKi responders remains underexp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribeiro, Marcelo Lima, Reyes-Garau, Diana, Vinyoles, Meritxell, Profitós Pelejà, Núria, Santos, Juliana Carvalho, Armengol, Marc, Fernández-Serrano, Miranda, Sedó Mor, Alícia, Bech-Serra, Joan J., Blecua, Pedro, Musulen, Eva, De La Torre, Carolina, Miskin, Hari, Esteller, Manel, Bosch, Francesc, Menéndez, Pablo, Normant, Emmanuel, Roué, Gaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401565/
https://www.ncbi.nlm.nih.gov/pubmed/34551904
http://dx.doi.org/10.1158/1078-0432.CCR-21-1067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401565/
https://www.ncbi.nlm.nih.gov/pubmed/34551904
http://dx.doi.org/10.1158/1078-0432.CCR-21-1067

Ejemplares similares